Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J
Background

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine.

Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine.

Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.

Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain.

Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults.

Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions
Acute Pain, Premature Ejaculation, Severe Pain, Acute, moderate, severe Pain, Moderate Pain
Associated Therapies
-

A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-02-03
Last Posted Date
2012-04-27
Lead Sponsor
Labopharm Inc.
Target Recruit Count
27
Registration Number
NCT00834808

Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study

Phase 4
Conditions
First Posted Date
2008-11-05
Last Posted Date
2009-02-13
Lead Sponsor
University of Southern Denmark
Target Recruit Count
12
Registration Number
NCT00785603

An Efficacy Study of Combination of Tramadol and Acetaminophen Tablets in the Treatment of Participants With Fibromyalgia Pain

First Posted Date
2008-10-06
Last Posted Date
2013-07-03
Lead Sponsor
Johnson & Johnson Taiwan Ltd
Target Recruit Count
80
Registration Number
NCT00766675

A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb

First Posted Date
2008-08-29
Last Posted Date
2018-12-04
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00743587
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

First Posted Date
2008-08-18
Last Posted Date
2016-03-31
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
328
Registration Number
NCT00737048

The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-08-13
Last Posted Date
2010-01-20
Lead Sponsor
Karolinska Institutet
Target Recruit Count
100
Registration Number
NCT00733421
Locations
🇸🇪

Foot & Ancle Surgical Center, Stockholm, Sweden

Tramadol Versus Fentanyl for Post-Operative Analgesia in Newborn Infants

First Posted Date
2008-07-11
Last Posted Date
2008-07-11
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
160
Registration Number
NCT00713726
Locations
🇧🇷

Albert Sabin Hospital, Fortaleza, Ceará, Brazil

A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-04-21
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
802
Registration Number
NCT00662558
Locations
🇺🇸

Pfizer Investigational Site, Weber City, Virginia, United States

© Copyright 2024. All Rights Reserved by MedPath